trending Market Intelligence /marketintelligence/en/news-insights/trending/U8X4vGUoYo1uOziV6DuZ4Q2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Seres Therapeutics ulcerative colitis drug nabs US FDA orphan drug designation

Blog

Needham & Company is Now Available in the S&P Global Market Intelligence Aftermarket Research Collection

Blog

Banking Essentials Newsletter - February Edition

Blog

Message in a (Word)Cloud

Six trends shaping the industries and sectors we cover in 2021


Seres Therapeutics ulcerative colitis drug nabs US FDA orphan drug designation

Seres Therapeutics Inc. said the U.S. Food and Drug Administration granted orphan drug designation to its SER-287 microbiome therapeutic candidate for treating pediatric patients with ulcerative colitis.

The designation follows a review of data from the phase 1b study evaluating SER-287 for ulcerative colitis treatment. The company expects results from the trial in early 2018.

Ulcerative colitis is a serious chronic condition affecting about 700,000 people in the U.S. The disease results in inflammation of the colon and rectum and may lead to colon removal.